185 related articles for article (PubMed ID: 37946031)
1. Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis.
Shide K; Takenaka K; Kitanaka A; Numata A; Kameda T; Yamauchi T; Inagaki A; Mizuno S; Takami A; Ito S; Hagihara M; Usuki K; Maekawa T; Sunami K; Ueda Y; Tsutsui M; Ando M; Komatsu N; Ozawa K; Kurokawa M; Arai S; Mitani K; Akashi K; Shimoda K
Ann Hematol; 2024 Jan; 103(1):97-103. PubMed ID: 37946031
[TBL] [Abstract][Full Text] [Related]
2. The evolving understanding of prognosis in post-essential thrombocythemia myelofibrosis and post-polycythemia vera myelofibrosis vs primary myelofibrosis.
Masarova L; Verstovsek S
Clin Adv Hematol Oncol; 2019 May; 17(5):299-307. PubMed ID: 31188809
[TBL] [Abstract][Full Text] [Related]
3. Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis.
Masarova L; Bose P; Daver N; Pemmaraju N; Newberry KJ; Manshouri T; Cortes J; Kantarjian HM; Verstovsek S
Leuk Res; 2017 Aug; 59():110-116. PubMed ID: 28601551
[TBL] [Abstract][Full Text] [Related]
4. Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter study
Palandri F; Palumbo GA; Iurlo A; Polverelli N; Benevolo G; Breccia M; Abruzzese E; Tiribelli M; Bonifacio M; Tieghi A; Isidori A; Martino B; Sgherza N; D'Adda M; Bergamaschi M; Crugnola M; Cavazzini F; Bosi C; Binotto G; Auteri G; Latagliata R; Ibatici A; Scaffidi L; Penna D; Cattaneo D; Soci F; Trawinska M; Russo D; Cuneo A; Semenzato G; Di Raimondo F; Aversa F; Lemoli RM; Heidel F; Reggiani MLB; Bartoletti D; Cavo M; Catani L; Vianelli N
Semin Hematol; 2018 Oct; 55(4):248-255. PubMed ID: 30502854
[TBL] [Abstract][Full Text] [Related]
5. A phase I study of panobinostat and ruxolitinib in patients with primary myelofibrosis (PMF) and post--polycythemia vera/essential thrombocythemia myelofibrosis (post--PV/ET MF).
Mascarenhas J; Marcellino BK; Lu M; Kremyanskaya M; Fabris F; Sandy L; Mehrotra M; Houldsworth J; Najfeld V; El Jamal S; Petersen B; Moshier E; Hoffman R
Leuk Res; 2020 Jan; 88():106272. PubMed ID: 31778911
[TBL] [Abstract][Full Text] [Related]
6. Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis.
Mesa RA; Tefferi A
Expert Opin Emerg Drugs; 2009 Sep; 14(3):471-9. PubMed ID: 19552608
[TBL] [Abstract][Full Text] [Related]
7. Clinicopathologic features and prognostic indicators in Chinese patients with myelofibrosis.
Gill H; Leung AY; Chan CC; Lau JS; Chan C; Yip SF; Liu H; Kho B; Mak V; Lee HK; Lin SY; Lau CK; Kwong YL
Hematology; 2016 Jan; 21(1):10-8. PubMed ID: 26292161
[TBL] [Abstract][Full Text] [Related]
8. Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.
Rotunno G; Pacilli A; Artusi V; Rumi E; Maffioli M; Delaini F; Brogi G; Fanelli T; Pancrazzi A; Pietra D; Bernardis I; Belotti C; Pieri L; Sant'Antonio E; Salmoiraghi S; Cilloni D; Rambaldi A; Passamonti F; Barbui T; Manfredini R; Cazzola M; Tagliafico E; Vannucchi AM; Guglielmelli P
Am J Hematol; 2016 Jul; 91(7):681-6. PubMed ID: 27037840
[TBL] [Abstract][Full Text] [Related]
9. The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis.
Hernández-Boluda JC; Pereira A; Gómez M; Boqué C; Ferrer-Marín F; Raya JM; García-Gutiérrez V; Kerguelen A; Xicoy B; Barba P; Martínez J; Luño E; Alvarez-Larrán A; Martínez-López J; Arbelo E; Besses C;
Haematologica; 2014 Apr; 99(4):e55-7. PubMed ID: 24488561
[No Abstract] [Full Text] [Related]
10. [Analysis of prognostic factors in Chinese patients with post-polycythemia vera myelofibrosis and post-essential thrombocythemia myelofibrosis].
Chen M; Xu ZF; Xu JQ; Li B; Zhang PH; Qin TJ; Zhang Y; Wang JY; Zhang HL; Fang LW; Pan LJ; Hu NB; Qu SQ; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2016 Oct; 37(10):876-880. PubMed ID: 27801320
[TBL] [Abstract][Full Text] [Related]
11. Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis.
Passamonti F; Mora B; Barraco D; Maffioli M
Curr Hematol Malig Rep; 2018 Jun; 13(3):173-182. PubMed ID: 29713873
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic Hematopoietic Stem Cell Transplantation for Post-essential Thrombocythemia and Post-polycythemia Vera Myelofibrosis.
Murata M; Suzuki R; Nishida T; Shirane S; Shimazu Y; Minami Y; Mori T; Doki N; Kanda Y; Uchida N; Tanaka M; Ishikawa J; Togitani K; Fukuda T; Ichinohe T; Atsuta Y; Nagamura-Inoue T; Kiyoi H
Intern Med; 2020; 59(16):1947-1956. PubMed ID: 32801269
[TBL] [Abstract][Full Text] [Related]
13. Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF).
Chen X; Williams WV; Sandor V; Yeleswaram S
J Clin Pharmacol; 2013 Jul; 53(7):721-30. PubMed ID: 23677817
[TBL] [Abstract][Full Text] [Related]
14. Prediction of thrombosis in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study on 1258 patients.
Mora B; Guglielmelli P; Kuykendall A; Rumi E; Maffioli M; Palandri F; De Stefano V; Caramella M; Salmoiraghi S; Kiladjian JJ; Gotlib J; Iurlo A; Cervantes F; Ruggeri M; Silver RT; Albano F; Benevolo G; Ross DM; Della Porta MG; Devos T; Rotunno G; Komrokji RS; Casetti IC; Merli M; Brociner M; Caramazza D; Auteri G; Barbui T; Cattaneo D; Bertù L; Arcaini L; Vannucchi AM; Passamonti F
Leukemia; 2022 Oct; 36(10):2453-2460. PubMed ID: 36042316
[TBL] [Abstract][Full Text] [Related]
15. Essential Thrombocythemia and Post-Essential Thrombocythemia Myelofibrosis: Updates on Diagnosis, Clinical Aspects, and Management.
Puglianini OC; Peker D; Zhang L; Papadantonakis N
Lab Med; 2023 Jan; 54(1):13-22. PubMed ID: 35960786
[TBL] [Abstract][Full Text] [Related]
16. Allogeneic hematopoietic stem cell transplantation in patients with polycythemia vera or essential thrombocythemia transformed to myelofibrosis or acute myeloid leukemia: a report from the MPN Subcommittee of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
Lussana F; Rambaldi A; Finazzi MC; van Biezen A; Scholten M; Oldani E; Carobbio A; Iacobelli S; Finke J; Nagler A; Volin L; Lamy T; Arnold R; Mohty M; Michallet M; de Witte T; Olavarria E; Kröger N
Haematologica; 2014 May; 99(5):916-21. PubMed ID: 24389309
[TBL] [Abstract][Full Text] [Related]
17. Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.
Masarova L; Alhuraiji A; Bose P; Daver N; Pemmaraju N; Cortes J; Pierce S; Kantarjian H; Verstovsek S
Eur J Haematol; 2018 Mar; 100(3):257-263. PubMed ID: 29226426
[TBL] [Abstract][Full Text] [Related]
18. The diagnosis and management of polycythemia vera, essential thrombocythemia, and primary myelofibrosis in the JAK2 V617F era.
Zhan H; Spivak JL
Clin Adv Hematol Oncol; 2009 May; 7(5):334-42. PubMed ID: 19521323
[TBL] [Abstract][Full Text] [Related]
19. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.
Barosi G; Mesa RA; Thiele J; Cervantes F; Campbell PJ; Verstovsek S; Dupriez B; Levine RL; Passamonti F; Gotlib J; Reilly JT; Vannucchi AM; Hanson CA; Solberg LA; Orazi A; Tefferi A;
Leukemia; 2008 Feb; 22(2):437-8. PubMed ID: 17728787
[No Abstract] [Full Text] [Related]
20. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
